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Introduction
The prognosis of cancer patients, even with localized primary tumors, is mainly determined by the circulation of tumor cells in the peripheral blood from the primary site to distant organs such as bone marrow, liver, lungs, or brain, and the subsequent outgrowth of a largely unknown subset of these cells into metastases in their new microenvironment (Eccles and Welch, 2007) . The colonization of distant organs by disseminated tumor cells, resulting in the appearance of clinically detectable metastases, can take many years in breast cancer (Braun et al., 2005) and the mechanisms behind this "cancer dormancy" are largely unknown (Chambers et al., 2002; Goss and Chambers, 2010; Uhr and Pantel, 2011) . This stringent selection process together with a potential independent genomic progression of disseminated tumor cells may explain why overt metastases can harbor unique genomic alterations differing from the bulk of the original primary tumor cells (Flatmark et al., 2002; Kang and Pantel, 2013; Riethdorf et al., 2010) . Thus, the direct analysis of metastatic cells could reveal important information for systemic cancer therapy targeting metastatic disease (Alix-Panabieres et al., 2012; Pantel et al., 2008) . However, biopsy of overt metastases is an invasive procedure limited to certain locations and not easily acceptable in the clinic. Moreover, a recent work has shown that different metastatic sites harbour different genomic aberrations (Gerlinger et al., 2012 ) and biopsy of one or two accessible metastases may not be representative of the whole metastatic disease biology.
An alternative approach is the analysis of blood samples for circulating tumor cells (CTCs) detection and characterization as a liquid biopsy of the cancer (Alix-M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT time monitoring of cancer therapies in individual patients (Alix-Panabieres et al., 2012) . Recent reports indicated that CTCs give important complementary information on therapeutic targets and drug resistance mechanisms in carcinoma patients (Alix-Panabieres and Pantel, 2014) . CTCs isolated in the peripheral blood are a pool of cells derived from the primary tumor and different metastatic sites and may, therefore, provide a comprehensive real-time picture of the whole tumor burden in an individual patient (Pantel and Alix-Panabieres, 2013) .
Characterization of tumor cells is of utmost importance. More specifically, PD-L1 expressed in tumors has been recently highlighted to function as a key component of the cancer-immunity cycle by preventing the immune system from destroying cancer cells (Butt and Mills, 2014) . PD-1 receptor (CD279) is expressed on the surface of activated T cells and its ligands, PD-L1 (B7-H1; CD274) and PD-L2 (B7-DC; CD273), are expressed on the surface of antigen-presenting cells such as macrophages or dendritic cells. When PD-L1 binds to PD-1, a strong inhibitory signal is transmitted into the T cell, which induces a reduction of cytokine production and a suppression of T-cell proliferation (Brahmer et al., 2012; Chen et al., 2012; Topalian et al., 2012) : the immune system is misled by the surrounding cancer cells expressing PD-L1 and does not destroy them.
Efforts to restore latent anti-tumor immunity have focused on antibody-based interventions targeting CTL antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) on T lymphocytes and its principal ligand (PD-L1) on tumor cells (Shin and Ribas, 2015) . Ipilimumab, an antibody targeting CTLA-4, appears to restore tumor immunity at the priming phase, whereas anti-PD-1/PD-L1 antibodies restore immune function in the tumor microenvironment. Although ipilimumab can produce durable long-term responses in patients with advanced melanoma, it is associated with M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT significant immune-related toxicities (Shin and Ribas, 2015) . By contrast, antibodies targeting either PD-1 or PD-L1 have produced significant anti-tumor activity with considerably less toxicity (Shin and Ribas, 2015) and are being actively investigated for the treatment of multiple cancers including lung, breast, bladder and renal cancers (Philips and Atkins, 2015) . Current efforts focus on registration trials of single agents and combinations in various diseases and settings, as well as on identifying predictive biomarkers of response. Ever since the earliest reports of the effects of PD-1 blockade, PD-L1 expression by tumor cells has been used as potential biomarker to predict a therapeutic response. We recently showed that the level of soluble PD-L1 present in the blood could predict patient's outcome in aggressive Bcell lymphomas (Rossille et al., 2014) . However, the predictive value of PDL1 expression measurements of primary carcinomas seems to be limited. Moreover, there is only a weak correlation in staining between the matched primary tumor and distant metastasis, suggesting that the primary tumor is not an adequate surrogate for determining PD-L1 expression in metastatic sites (Jilaveanu et al., 2014) . Tissue heterogeneity in PD-L1 expression in both primary and metastatic sites for a given patient indicates that a single core biopsy might be not sufficient to determine tumor PD-L1 expression (Jilaveanu et al., 2014) .
CTCs are currently investigated as predictive biomarker for HER2-targeting therapies (Bidard et al., 2013) 
2.
Materials and methods
Patient samples and blood collection
After informed consent was given, peripheral blood from patients with hormone receptor-positive (HR + ), HER2-negative (HER2 -) metastatic breast cancer was collected before the start of treatment (CPP number 2011-AOI163-38 et al., 2011) . This study belongs to the BMS_PD-L1_onco clinical trial (NCT10660776), which assesses PD-L1 as a biomarker in oncology and hematology.
Cell culture
Mammary cancer cell lines SKBR3 (ATCC® HTB-30™), MCF7 (ATCC® HTB-22™),
MDA-MB-231 (ATCC® CRMHTB-26™) were purchased from the American Type 
cm2 flasks at 37°C in a humidified atmosphere conta ining 5% CO2.
CTC enumeration
Seven and half milliliters of blood collected in the CellSave tube were used for CTC detection using the FDA-cleared CellSearch ® system (Janssen, Beerse, Belgium).
Blood samples were processed on the CellTracks Autoprep within 72h. The CTCs were identified as EpCAM (+) DAPI (+) CK (+) CD45 (-) .
As control group, we analysed in parallel blood samples from 15 healthy controls provided by the regional centre of blood transfusion (Etablissement Français du Sang of Montpellier, France).
Flow cytometry experiments
A fixation/permeabilization kit (Beckman Coulter, Brea, USA) was used to prepare the cells before the addition of the anti-human B7H1 Ab or Mouse IgG1 PE at a final concentration of 20 µg/mL on 0.2 million SKBR3 cells and 0.2 SU-DHL-4. Briefly, cells and both Abs were incubated for 60 min at room temperature in the dark. Cells were then washed with PBS supplemented with 2% fetal bovine serum, centrifuged (600g -5 min) and the cell pellet was recovered with 400µL PBS. Labelled cancer cells were detected by using the Cyan cytometer (Beckman Coulter) and the data analysis was performed using the Kaluza software (Beckman Coulter).
Other anti-human B7H1 Abs have been tested: (1) MAb, (Cat N° FAB1561P, R&D Systems; data given by R &D systems).
Immunocytochemical analyses
SKBR3 cancer cells were labelled as described above using the concentration of the anti-human B7-H1 MAb required for the CellSearch ® system (20 µg/mL) and Figure 2B ) and immunofluorescent staining of cytospins (Figure 2C) . The specificity of the staining was demonstrated by the fact that no signals were detected for the cell line SU-DHL-4 (established negative control) and for the isotype control on SKBR3 cells. Next, SKBR3 (PD-L1 (+) ) and SU-DHL-4 (PD-L1 (-) ) were analyzed for PD-L1
using the CellSearch ® system with PD-L1 implemented in the 4th channel (Fig. 2D) .
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We selected the anti-human B7-H1/PD-L1 PE-conjugated monoclonal antibody (MAb) from R&D. Other anti-human B7H1 Abs have been also tested at different concentrations with the CellSearch ® system: (1) When we performed additional experiments with the CellSearch ® system dedicated for CTC detection on pure SKBR3, we could observe single PD-L1 (+) SKBR3 tumor cells ( Figure 3A) as well as clusters (Figure 3B ) of PD-L1 (+) SKBR3 tumor cells.
Moreover, we defined a "PD-L1 immunoscore" with three different scores for the intensity of PD-L1 expression by single SKBR3 tumor cells and SKBR3 tumor cell clusters: score 0 (no PD-L1 expression), score 1 (low PD-L1 expression) and score 2 (high PD-L1 expression) (Figure 3) .
Spiking experiments of SKBR3 in control blood
We performed spiking experiments by adding 200 SKBR3 cells in 7.5 mL of blood from healthy donors and detected the breast cancer cells using the CellSearch ® system with the CellSearch ® CXC Kit. These results demonstrated the feasibility to detect PD-L1 (+) tumor cells in blood samples with this technology dedicated for CTC detection. SKBR3 cells could be detected with a recovery rate of 79.5%, which is consistent with the results obtained the standard CTC kit (Riethdorf et al., 2007) .
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PD-L1 (+) CTC from metastatic breast cancer patients
Peripheral blood samples from HR (+) , HER2 (-) Eleven patients out of 16 showed a subpopulation of CTCs expressing PD-L1
(68.8%) scored 1 or 2 (Table 2; Figure 4A) . The fraction of PD-L1 (+) CTCs varied from 0.2 to 100% ( Table 2) . However, this information may also depend on the number of detected CTCs. If only patients with more or equal than 10 CTCs are considered, the fraction of PD-L1 (+) CTCs varied from 0.2 to 50% ( Table 2) . The intensity of PD-L1 staining varied between patients and within the same blood sample. Analyzing samples with multiple CTCs showed that six patients had CTCs with mixed PDL1 phenotypes (immunoscores 1 and 2), whereas homogeneous PDL1 immunoscores were only found in one patient ( Table 2) .
As shown in the Figure 4B , we could also easily observe and distinguish PD-L1 (+) leucocytes next to CTCs positive or not for the expression of PD-L1. Leucocytes express CD45, while CTCs are defined in the CellSearch ® system as CD45 (-) .
As negative controls, we tested blood samples from 15 healthy controls and confirmed that none of the samples were positive for CTCs (Data not shown).
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Discussion
In the present paper, we provide evidence that PD-L1 is frequently expressed on metastatic cells circulating in the blood of HR (+) , HER2 (-) breast cancer patients. To our best knowledge, this is the first report demonstrating the expression of PD-L1 on CTCs in any cancer entity. Detection of CTCs expressing PD-L1 means that the patients harbor metastatic tumor cells that may have the capacity to block the immune system. These cells are potential targets for anti-PDL1 therapies. This information is fundamentally different from the detection of shed PD-L1 in the blood serum or plasma, which provides no information on the cellular source of PD-L1.
The sensitivity, specificity and the dynamic range of the PD-L1 MAb that we chose in our study was determined by Western Blot, flow cytometry and immunocytochemical analyses. We tested different mammary cancer cell lines (i.e., MDA-MB-231, MCF-7 & SKBR3) and as PD-L1 was expressed at variable degrees on SKBR3, we selected it as our positive control for the establishment of our novel assay detecting CTCs expressing PD-L1. We could thus established immunoscores for PD-L1 expression on single SKBR3 cells with this anti-human B7-H1 MAb and then validated these scores on blood samples from patients with a HR (+) , HER2 (-) metastatic breast cancer. This strategy has been adapted from previous reports using the CellSearch ® system for immunophenotyping of CTCs (Ignatiadis et al., 2011; Riethdorf et al., 2010) .
Despite the fact that we only analyzed a limited number of patients, our results clearly showed that PD-L1 is frequently expressed on CTCs. However, the As an alternative, we previously introduced a new diagnostic concept called "liquid biopsy" (Alix-Panabieres and Pantel, 2013; Pantel and Alix-Panabieres, 2010) . 
